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INTRODUCTION 
HIV-1 RNA quantitative evaluation is used worldwide as a 
prognostic marker, to predict the risk of clinical progres-
sion of HIV-1 infection, and as an efficacy marker, to mon-
itor therapeutic response (Mellors at al., 1997). Indeed, 
the aim of combined antiretroviral therapy (cART) is to 
achieve permanently undetectable HIV-1 RNA. Real-time 
nucleic acid amplification technologies are currently rec-
ommended to detect and measure HIV-1 RNA and gene 
sequencing techniques are used to perform HIV-1 geno-
type analysis (DHHS, 2014). Several automated assays are 
commercially available. Nevertheless, recent studies have 
shown discrepancies in viral load estimation among the 
existing commercial quantitative assays, especially for 
the quantification of non-B subtype strains (Bourlet et al., 
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the number of patients newly infected by non-B subtypes 
is increasing (Santoro et al., 2013; Siemieniuk et al., 2013). 
In Italy, CRF02_AG is one of the most common non-B sub-
types (Santoro et al., 2012). Since HIV-1 RNA has major 
implications in therapeutic choices, clinicians should con-
sider the possibility of discrepant HIV-1 RNA quantifica-
tions using different quantitative assays while approach-
ing a patient infected by a non-B subtype. Here we report 
on a primary HIV-1 infection caused by a CRF02_AG in 
a Caucasian patient, in whom two different HIV-1 RNA 
amplification assays detected different values of viral load 
in the same plasma sample.
CASE REPORT
In July 2014, a 48 year-old man developed an acute febrile 
syndrome accompanied by sore throat, nausea, vomiting, 
diarrhea and fatigue. He reported a history of unprotected 
sexual intercourse in the last two months. He was given 
a two-week empirical antibiotic treatment by his family 
doctor without clinical improvement. Because of the per-
sistence of symptoms, he was then admitted to our In-
fectious Diseases Unit in Genoa, Italy. On admission, he 
was afebrile, alert and cooperative. Physical examination 
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showed enlargement of laterocervical, retronucal and in-
guinal lymph nodes, which had tense-elastic consistency 
and were mobile. Abdominal examination revealed liver 
and spleen enlargement, with no other abnormality. Lab-
oratory examinations showed normal blood cell counts 
and renal function, while liver enzymes were slightly in-
creased (AST 41 U/L, normal value <50 U/L; ALT 96 U/L 
normal value <50 U/L). Serological tests for mononucleo-
sis-like syndromes were performed. HIV test resulted pos-
itive using a fourth generation HIV-1/2 assay (Vironostika® 
HIVAg/Ab, BioMérieux). The result was confirmed by an-
other fourth generation HIV-1/2 assay (GenscreenTM UL-
TRA HIV Ag-Ab, Bio-Rad). In order to confirm the clinical 
suspicion of primary HIV-1 infection, an anti-HIV-1 West-
ern Blot (New Lav Blot I, Bio-Rad), avidity test and HIV-1 
RNA (Nuclisens EasyQ® HIV-1 2.0, BioMérieux SA) (EQ) 
were also performed. The Western Blot revealed reactivity 
to gp160 and a very weak, uncertain positivity to gp120 
band: according to the WHO criteria this test resulted in-
determinate. The avidity test showed an avidity index of 
0.57%; HIV-1 RNA was 6,700 copies/ml; CD4+ cell-count 
was 523/mm3 (17,1%) with a 0.2 CD4+/CD8+ T-cell ratio. 
Therefore, according to clinical history and immune-viro-
logical results, a primary HIV-1 infection was diagnosed 
(classified as A1 stage, following CDC classification). A few 
days later, the HIV-1 genotypic resistance test, obtained 
using Trugene HIV-1 Genotyping kit (Siemens Health Care 
Diagnostics), revealed no resistance mutations in the tran-
scriptase gene, but some mutations in the protease gene 
including L10I, K20I, M36I, and M46I (Table 1). More-
over, the analysis performed with REGA HIV-1 Subtyping 
Tool - Version 3.0 attributed the HIV-1 sequence to the 
CRF02_AG recombinant form. At this point all laboratory 
tests were confirming the clinical impression of a prima-
ry HIV-1 infection, thus requiring immediate initiation of 
cART. Because of his low viral load the patient was put on 
a single tablet regimen with tenofovir, emtricitabine and 
rilpivirine (EACS, 2014). However, when the virus was se-
quenced and identified as a CRF02_AG recombinant form, 
a second real-time PCR assay was performed on an addi-
tional aliquot of the same sample tested with Nuclisens 
EasyQ®, using the Versant® HIV-1 RNA 1.0 Assay (kPCR) 
(Siemens HealthCare Diagnostics). This assay revealed a 
HIV-1 RNA of 230,000 copies/ml. Thus, cART was potenti-
ated by adding an integrase inhibitor. By using kPCR, two 
weeks later, HIV-1 RNA was 104 copies/ml and after an 18 
week course of four-drug cART, the viral load was 38 cop-
ies/ml. At the same time points, the EQ assay detected an 
HIV-1 RNA of 40 copies/ml and undetectable (<10 copies/
ml), respectively (Table 2).
DISCUSSION 
HIV-1 is characterized by high genetic variability, due 
to the large number of errors made by the reverse tran-
scriptase enzyme, in a setting of high viral replication and 
host immunological pressure. The majority of HIV-1 vi-
ral forms circulating in Europe belong to the M group, B 
subtype. However, the number of patients newly infected 
by non-B subtypes and by HIV-1 CRFs, which result from 
the recombination of different HIV-1 subtypes, is rising. 
In particular, according to Hemelaar et al. (2011), from 
2001 to 2007 the prevalence of the recombinant form 
CRF02_AG increased from 5.4 to 7.7% globally, with a ma-
jor growth in African countries. However, a major increase 
was also observed in Western and Central Europe, where 
CRF02_AG accounted for 2.9% of HIV-1 infections at the 
beginning of the study period and for 4.5% at the end of 
2007 (Hemelaar et al., 2011). In Italy, the prevalence of 
non-B strains increased from 2.6% in 1980-1992 to 18.9% 
in 1993-2008 (Lai et al., 2010), and the most prevalent 
non-B subtype are currently C, F and CRF02_AG (Santoro 
et al., 2012). This phenomenon is most likely due to the in-
creasing number of migrants and travellers from areas of 
high HIV-1 prevalence where non-B subtypes are the pre-
dominant variant. Knowing and investigating the spread 
of non-B strains is not only essential for epidemiological 
and clinical reasons but also for laboratory implications. 
Indeed, the wide genetic variability of HIV-1 subtypes may 
affect the capability of the commonly used assays to de-
Table 1 - Patient’s HIV-1 genotypic resistance test.
Protease gene
Resistance mutations 10I 13V 20I 36I 46I
Other mutations 14R 15V 16E 39S 41K 43R 63Q 64L 69K 70R 89M
Polymerase gene
Resistance mutations None
Other mutations 37F 39A 45R 60I 123E 135V 162A 173A 174K 177E 200A 207E 245Q
Integrase gene
Resistance mutations None
Other mutations 101I 111Q 112V 124A 125A 133T 134N 135V 136T
Table 2 - HIV-1 RNA (copies/ml) using different assays at baseline evaluation and after 2 and 18 weeks of combined antiretroviral therapy 
(cART).
Nuclisens EasyQ® HIV-1 2.0 Versant® HIV-1 RNA 1.0 Assay (kPCR)
Baseline 6,700 230,000
Week 2 40 104
Week 18 <3 38
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tect and accurately quantify HIV-1 RNA in non-B subtypes 
and CRFs, as previously reported in African experienc-
es (Peeters et al., 2010; Luft et al., 2011; Bruzzone et al., 
2014), as well as in European series (Holguin et al., 2008). 
Despite primers and probes used in the commercial HIV-1 
RNA test are designed to annealing the most conserved re-
gion of HIV-1 virus, it is impossible for them to recognize 
all HIV-1 strains with the same efficiency. To investigate 
the concordance among the newly and commonly used 
assays [EQ, Abbott RealTime HIV-1 (m2000sp/rt), CO-
BAS AmpliPrep/COBAS Taqman® HIV-1 test v2.0 (CTM) 
and kPCR] several studies were carried out. On the whole, 
all assays show a good correlation and concordance with 
each other. 
Only small differences were observed. Briefly, EQ assay in 
comparison with the others shows an under-quantifica-
tion of HIV-1 RNA, mainly for G subtypes and CRF02_AG 
(Gomes et al., 2013; Ndiaje et al., 2015); the quantitative 
values obtained using kPCR assay were usually lower than 
those obtained by CTM assay (Troppan KT et al., 2009) 
whilst the quantitative values obtained using CTM, mainly 
for B subtypes, (Bourlet T et al., 2011) were usually higher 
than those obtained by EQ and m2000sp/rt assays (Ndiaje 
et al., 2015). 
The discrepancy in the detection and/or quantification of 
some subtypes and CRFs between the used tests may be 
due to differences in technology platforms but, above all, 
to the target region of viral genome that each assay uses. 
The gag gene targeted by the EQ assay is less conserved 
than others such as the pol-int gene (m2000sp/rt, CTM 
and kPCR) and LTR region (CTM). The under-quantifica-
tion by EQ may be related to primer and probe mismatch-
es in the gag target region whilst the over-quantification by 
CTM may be due to the amplification of double target: gag 
and LTR (Ndiaje et al., 2015).
In such scenario, the method that measures the highest 
value of viremia in the same sample should be consid-
ered the most reliable. A non-B subtypes or CRF HIV-1 
strain infection should be suspected when lower than ex-
pected viral load values are found. In the above-described 
case, several factors were in accordance with a diagnosis 
of HIV-1 acute infection (a history of recent unprotected 
sexual intercourse, the mononucleosis-like syndrome and 
the typical indeterminate Western Blot test report): there-
fore, high levels of HIV-1 RNA were expected. Surprising-
ly, the HIV-1 RNA resulted 6,700 copies/ml. Nevertheless, 
when the genotypic resistance test revealed a CRF02_AG 
strain, the need of a second, different HIV-1 RNA test on 
the same samples was clear. The second result (230,000 
copies/ml), two logarithms higher than the first one, was 
certainly more consistent with the clinical picture, and led 
to the choice of potentiating the ongoing cART with the 
addition of suitable drug against >100,000 copies/ml vi-
ral loads. The subsequent HIV-1 RNA controls, performed 
with both the virological assays, confirmed the discrepan-
cy between the two tests. Finally, as previously reported, in 
the protease gene the following amino acids substitutions 
were detected: L10I, K20I, M36I, and M46I. In subtype 
B, the 10I, 20I and 36I mutations contribute to second-
ary resistance to protease inhibitors (PIs) whereas the 46I 
mutation reduces susceptibility to atazanavir, fosampre-
navir, indinavir, lopinavir and nelfinavir (Rhee et al., 2010) 
and increases the PIs catalytic efficiency (Henderson et al., 
2012). However, in CRF02_AG the 20I is wild type, the 36I 
is detected in 99% of CRF02_AG (Taylor et al., 2008) and 
the real meaning of the 46I is unknown, although caution 
in PIs use is advisable.
In conclusion, physicians should be aware of the critical 
issues they might find when interpreting laboratory results 
of non-B HIV-1 infection, also because of possible implica-
tions in the therapeutic choices. Dialogue with virologists 
should be sought and can prove crucial whenever clinical 
and laboratory data seem not to match properly.
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